Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 3, Pages 294-+Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.21.02040
Keywords
-
Categories
Funding
- Intramural Research Program of the National Cancer Institute, National Institutes of Health
Ask authors/readers for more resources
Summary: "Clinical Oncology": HIV-associated Kaposi sarcoma (HIV+KS) is a persistent malignancy, particularly common in sub-Saharan Africa. The relapsing and remitting nature of the cancer can lead to significant long-term morbidity for patients, and concurrent diseases may contribute to mortality. T-cell-sparing options are important for the treatment of HIV+KS.
The observation in 1981 of the emergence of Kaposi sarcoma (KS) among young men who had sex with men was one of the first harbingers of the HIV epidemic. With advances in HIV care, the incidence of HIV-associated KS (HIV+KS) has decreased over time in the United States. However, it remains a persistent malignancy among some HIV-infected populations and is one of the most common tumors in sub-Saharan Africa. Because of the relapsing and remitting nature of this cancer, patients with HIV+KS can experience significant, long-term, morbidity. Patients with severe HIV+KS may also have concurrent lymphoproliferative syndromes, malignancies, and/or infections that can contribute to mortality. Several chemotherapy agents were explored in clinical trials for HIV+KS during the early stage of the epidemic. As HIV+KS emerges with CD4 lymphopenia and immunodysregulation, T-cell-sparing options are important to consider. Here, we explore the pathogenesis of HIV+KS and the current evidence for immunotherapy and therapies that potentially target KS pathogenesis. This review provides the current landscape of therapies for HIV+KS and highlights management issues for patients with HIV and cancer. (C) 2021 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available